April 2026 Glaucoma Trial Launches: A Global Landscape Review

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/april-2026-glaucoma-trial-launches-a-global-landscape-reviewTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:April 2026 Glaucoma Trial Launches: A Global Landscape Review Glaucoma is a leading cause of irreversible blindness worldwide. An estimated 76 million people had glaucoma in 2020, with that number projected to exceed 111 million by 2040 (). Most glaucoma treatments work by lowering intraocular pressure (IOP), the fluid pressure inside the eye, but new therapies aim to protect nerve cells and preserve vision. In April 2026 dozens of new glaucoma clinical trials officially began in registries around the world (ClinicalTrials.gov, EU CTR, ISRCTN, ANZCTR, CTRI, ChiCTR, WHO ICTRP). These trials span a range of intervention types – including new medications, implants and devices, surgical procedures, and digital health tools – and together paint a picture of current research priorities. New Trials by Modality The April 2026 trials can be grouped by their main intervention modality: Drug (Medication) Trials: The largest category remains medication studies. These include novel eye drops that lower IOP (for example new prostaglandin analogues or rho-kinase inhibitors) as well as systemic drugs being repurposed. Recent years have seen interest in metabolic and neuroprotective agents – for example, trials of oral diabetes drugs (GLP-1 agonists) or vitamins that may protect retinal nerve cells () (). Some trials involve sustained-release formulations (tiny implants that slowly release IOP-lowering drugs). For instance, one ongoing Phase II study is testing a tiny biodegradable implant (“TimoD”) that slowly releases the glaucoma drug timolol (). Overall, most new trials are early-stage (Phase I/II) safety and efficacy studies of such medications and delivery systems. Device Trials: A substantial portion of trials involve medical devices and implants. This includes micro-invasive glaucoma surgery (MIGS) devices, drainage stents and shunts, and laser or ultrasound systems to improve outflow. Examples might be trials of new canaloplasty implants or trabecular bypass stents, or innovative lasers (like excimer laser trabeculotomy) that create tiny drains in the trabecular meshwork. Many device trials test ways to restore the eye’s natural drainage (e.g. new iris-to-canal shunts) or to replace medications with implants. These often require surgical implantation but are generally less invasive than traditional trabeculectomy. Surgical and Procedural Trials: Some studies focus on surgical techniques rather than implants. These include comparisons of different glaucoma surgeries (for example combined cataract–glaucoma procedures versus standard surgery), or novel approaches like minimally penetrative trabeculotomies. A few are evaluating high-intensity focused ultrasound or other non-implant procedures to lower IOP. (In practice there is overlap with device trials, since many surgical trials involve an implanted device.) Digital and Diagnostic Trials: A growing niche is digital health. These trials evaluate tools like smartphone perimetry apps, home tonometry devices, AI algorithms for image screening, or telemedicine programs for remote care. For example, a recent trial is using an AI system to flag glaucoma from routine retinal photos in primary care clinics. A systematic review found 21 published studies of home-based glaucoma monitoring tools (portable visual field tests and tonometers), all showing “results closely matchiSupport the show